NORTH CHICAGO, Ill., May 14, 2025 - AbbVie Inc. $(ABBV)$ has announced that EMRELIS™ (telisotuzumab vedotin-tllv) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, who have previously undergone systemic therapy. This approval marks a significant milestone as EMRELIS is the first and only treatment available for this specific group of NSCLC patients, who often face limited treatment options and poor prognosis. The FDA had earlier granted EMRELIS Breakthrough Therapy Designation based on the Phase 2 LUMINOSITY study data. The drug is currently being further evaluated in a randomized Phase 3 confirmatory global study, TeliMET NSCLC-01, with patient enrollment underway. Additionally, the FDA has approved the Roche VENTANA® MET (SP44) RxDx Assay as the companion diagnostic to identify eligible patients for EMRELIS treatment.